BioSpace News Archive

Sierra Oncology reported preclinical data supporting the ongoing clinical development strategy for its Chk1 inhibitor, SRA737.

vTv is currently studying azeliragon in two identical, randomized, double-blind, placebo-controlled Phase 3 trials investigating its efficacy as a potential treatment of mild Alzheimer’s disease.

The NovoStitch Plus device allows orthopaedic surgeons to address horizontal, radial, and other complex meniscal tears in ways not previously possible.

The type II variation submitted is based on data from CheckMate -238, an ongoing phase 3, randomized double-blind study of Opdivo 3 mg/kg versus Yervoy (ipilimumab) 10 mg/kg in patients who have undergone complete resection of stage IIIb/c or stage IV melanoma, in which Opdivo met its primary endpoint of recurrence-free survival.

Appili plans to conduct the ATI-1501 clinical study in Toronto, Ontario and will begin recruiting subjects in November 2017.

Aries Pharmaceuticals, Cosmo’s U.S. subsidiary based in San Diego, California, will lead the commercial sales and marketing for Aemcolo in the U.S.

The goal of this Phase 2 trial is to evaluate both the efficacy and safety of poziotinib in patients with non-small cell lung cancer (NSCLC) that is locally advanced or metastatic and have an exon 20 insertion mutation in either EGFR or HER2.

Aethlon Medical today announced it will issue financial results for the second quarter fiscal year 2018 ended September 30, 2017 at 4:15pm eastern time on Thursday, November 2, 2017.

Mercator MedSystems announced completion of enrollment today in the company’s LIMBO-ATX designed to use Mercator’s proprietary Bullfrog micro-infusion catheter

Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a business update.